BUSINESS

Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings

December 20, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) earned much-awaited approval on December 19 for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC) for use in both first-line and second-line settings. Keytruda was approved in Japan in September…

To read the full story

Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016

BUSINESS

Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
Tanabe Starts Long-Term Uplizna Study in IgG4-Related Disease
June 25, 2026
ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
Tacrolimus Generics Add Cell Transplantation Indication
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…